Exparel and Education to Avoid Opioids After Carpal Tunnel Release
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03867539 |
|
Recruitment Status :
Recruiting
First Posted : March 8, 2019
Last Update Posted : March 9, 2023
|
Sponsor:
Kettering Health Network
Collaborator:
American Society for Surgery of the Hand
Information provided by (Responsible Party):
Kettering Health Network
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This trial seeks to use the long acting local anesthetic Exparel, in conjunction with opioid education, to attempt to avoid any post-operative opioid use following carpal tunnel surgery. This group will be compared with a "standard" group that receives non-liposomal bupivacaine, opioid education, and opioids.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Carpal Tunnel Syndrome | Other: Differing pain management strategy | Phase 4 |
As has become apparent in the media, as well as in the clinical practice of nearly every type of medicine over the last few years, the nation is currently experiencing an opioid epidemic. This is a significant public health issue that has sweeping consequences that reach far beyond the medical field. The investigators believe over the last several decades, public perception regarding pain, especially post-operatively, has changed for the worse. The nation is in need of a paradigm shift in the way pain is managed, and the way the public perceives this issue, especially regarding pain expectations. As patients have become more involved with medical care as well as more knowledgeable, the investigators often see patients having performed online research regarding outcomes and expectations following particular procedures, to include post-operative pain. Commonly, even for smaller procedures performed in office, patients request opioids. As of yet, there are few data regarding use of long acting (Exparel) local analgesia alone in hand surgery, and none combining this strategy with pre-operative opioid education. The goal is to build the groundwork for the cessation of opioid prescription following carpal tunnel surgery, and produce proof that may be given patients to showing this to be an effective strategy. As some sources estimate 400,000 carpal tunnel surgeries are performed yearly, it is believed that this alternative pain management strategy, if adopted at a national level, would make a significant step towards remedying the current crisis. The rationale as to why this will be successful is the duration of action of Exparel, which has been shown to be effective for up to 72 hours. By 72 hours, post-procedure pain levels tend to have dropped precipitously, if not resolved. Use of pre-operative opioid education has also been shown to decrease perception of the need for and use of opioids. The investigators plan to study two groups: a control/standard of care group, that are given pre-operative opioid education as well as opioids, and a study group, which will have pre-operative opioid education, Exparel injection, and no opioids. Exparel will be administered as 10cc injected in the operative field, consisting of ~5cc of Exparel, ~5cc of bupivacaine, and epinephrine. All injections will be performed in the same manner. Following injection, carpal tunnel release will be performed in a similar manner in all patients. Patients that meet all of the inclusion and none of the exclusion criteria would be eligible for participation. If a patient agreed to participate, they would be randomized to group A (standard of care + education), or group B (Exparel + education + no opioids). This would be accomplished by drawing an A or B written on a paper ticket out of a bag. Adverse reactions and pain levels at 24, 48, and 72 hours will be assessed with telephone or email questionnaire, as will use of medication in the opioid group. Statistical analysis will be performed using analysis of variance, Mann-Whitney U test, and/or chi square test, as appropriate. The public health relevance of this project is to alter patient's perceived need for opioid medications post procedure, and decrease the amount of circulating opioids locally and nationally. The investigators believe this a meritorious goal, given that opioid related overdose deaths have increased eight-fold from 2012 to 2016.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 64 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Care Provider) |
| Primary Purpose: | Supportive Care |
| Official Title: | Exparel and Education to Avoid Opioids After Carpal Tunnel Release |
| Actual Study Start Date : | February 15, 2019 |
| Estimated Primary Completion Date : | March 31, 2024 |
| Estimated Study Completion Date : | March 31, 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Carpal tunnel syndrome
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Control Group; Bupivacaine + opioids
This is the "standard of care" arm. This group will receive pre-operative opioid education and "standard of care", which consists of an injection of 10cc bupivacaine (plus ~1cc epinephrine and bicarbonate) into the carpal tunnel and overlying skin pre-operatively, and a post operative prescription for opioids (oxycodone/acetaminophen 5/325). Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies.
|
Other: Differing pain management strategy
The investigators aim to investigate an alternative (vs "standard") pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated. |
|
Experimental: Experimental Group: Exparel, no opioids
This group will receive pre-operative opioid education, Exparel injection (liposomal bupivacaine, with bupivacaine, epinephrine and bicarbonate), and would not receive a prescription for opioids. This injection will be administered as 10cc injected in the operative field, consisting of ~5cc of Exparel (liposomal bupivacaine), ~5cc of bupivacaine, and ~1cc epinephrine. Pain scores and medication usage will be tracked for three days post operatively to assess the validity and efficacy of differing pain management strategies.
|
Other: Differing pain management strategy
The investigators aim to investigate an alternative (vs "standard") pain management strategy for post operative carpal tunnel release. All drugs used are FDA approved for these indications, and no drug itself is being investigated. |
Primary Outcome Measures :
- Evaluation of post operative pain levels via Visual Analog Scale [ Time Frame: Within the first few months of study duration ]The investigators aim to evaluate pain in either arm of the study, followed over a three day course. As several studies have shown pain to be wholly or mostly resolved by post-operative day three. Patients will answer questionnaire to include Visual Analog Scale for pain, and amount of pain medication taken. The Visual Analog Scale for pain ranges from a score of 0 to 10, with 0 being "no pain", 5 being "distressing pain", and 10 being "the worst pain imaginable"
Secondary Outcome Measures :
- Failure of alternate pain management strategy [ Time Frame: Within the first few months of study duration ]The investigators aim to identify any subset of patients that do not respond to combination therapy (education + Exparel). Analysis of data provided by patient-answered Visual Analog Scale will occur. Failures will be presented as a whole number and as percentage of total participants.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- carpal tunnel syndrome diagnosed either by physical exam or EMG
- age >18.
Exclusion Criteria:
- allergy to bupivacaine
- pre-operative opioid usage within the last six months
- patients allergic to Percocet or acetaminophen
- patients taking tricyclic antidepressants (interaction with bupivacaine)
- vulnerable populations (prisoners or pregnant women)
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03867539
Contacts
| Contact: Ronald Buczek, DO | 937-439-6483 | orthostudy2019@gmail.com |
Locations
| United States, Ohio | |
| Orthopedic Associates of Southwest Ohio | Recruiting |
| Dayton, Ohio, United States, 45414 | |
| Contact: Laura Peterson 937-439-6483 lpeterson@oaswo.com | |
| Principal Investigator: Ronald Buczek, DO | |
| Orthopedic Associates of Southwest Ohio | Recruiting |
| Dayton, Ohio, United States, 45459 | |
| Contact: Laura Peterson 937-439-6483 | |
| Principal Investigator: Ronald Buczek, DO | |
Sponsors and Collaborators
Kettering Health Network
American Society for Surgery of the Hand
Investigators
| Principal Investigator: | Ronald Buczek, DO | Kettering Health Network |
Publications of Results:
Other Publications:
Other Publications:
| Responsible Party: | Kettering Health Network |
| ClinicalTrials.gov Identifier: | NCT03867539 |
| Other Study ID Numbers: |
6012435 |
| First Posted: | March 8, 2019 Key Record Dates |
| Last Update Posted: | March 9, 2023 |
| Last Verified: | December 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
Keywords provided by Kettering Health Network:
|
hand exparel opioid crisis |
Additional relevant MeSH terms:
|
Carpal Tunnel Syndrome Median Neuropathy Mononeuropathies Peripheral Nervous System Diseases Neuromuscular Diseases |
Nervous System Diseases Nerve Compression Syndromes Cumulative Trauma Disorders Sprains and Strains Wounds and Injuries |